Zydus Lifesciences Ltd (ZYDUSLIFE)

Zydus Lifesciences Ltd (ZYDUSLIFE) is listed on the NSE in the Pharmaceuticals sector, Pharmaceuticals & Biotechnology industry. Market capitalisation: 117705.45 Cr. Figures below are as reported and are shown with their source and date.

Educational use only — GoQuant is a research tool. This page lists company facts only and is not a recommendation. Investment advice is provided by FINOME TECHNOLOGIES PVT LTD (AltQube), SEBI-registered Investment Adviser, registration no. INA000018373, under a signed advisory agreement and after a risk profile. Past performance is not indicative of future results.

Company profile

Sector
Pharmaceuticals
Industry
Pharmaceuticals & Biotechnology
Market cap (₹ Cr)
1,17,705.45

Zydus Lifesciences Ltd. engages in the discovery, development, and manufacture of pharmaceutical products under Zydus brand. The company is headquartered in Ahmedabad, Gujarat and currently employs 23,026 full-time employees. The firm is engaged in the research and development, manufacturing, marketing and selling of finished dosage human formulations, such as generics and specialty formulations, including biosimilars and vaccines; active pharmaceutical ingredients (APIs); animal healthcare products, and consumer wellness products. Its products include Bilypsa (saroglitizar), Oxemia (desidustat), Ujvira (biosimilar Kadcyla), and Exemptia. The company offers Bilypsa drug for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Desidustat is an oral, small molecule hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitor, which is used for the treatment of anemia in chronic kidney disease (CKD) patients. The company is also developing an oral small molecule ZYIL1, targeted at selectively suppressing inflammation caused by the NLRP3 inflammasome. Its ZyCoV-D is a plasmid deoxyribonucleic acid (DNA) vaccine for COVID-19.

Source: finedge · as of 2026-09-29

Price, last year

Last close (₹): 1,135

Source: quantro_screener_metrics_job · as of 2026-10-22

Key figures

P/E
22.66
52-week high
1,232.1
52-week low
835.5
Revenue CAGR, 3 years (%)
16.35
Revenue CAGR, 5 years (%)
12.45
EPS CAGR, 3 years (%)
37.26
EPS CAGR, 5 years (%)
19.17

Source: quantro_screener_metrics_job · as of 2026-10-23

Annual summary

Year endedRevenue (₹ Cr)PAT (₹ Cr)EPS (₹)
Mar 202627,148.45,04050.09
Mar 202523,241.5147.11.46
Mar 202419,547.4113.31.13
Mar 202317,237.41,960.319.37
Mar 202215,265.24,487.343.83

Source: finedge · as of 2026-07-21

Shareholding and promoter pledge

Promoter
75%
FII
6.95%
DII
11.2%
Public
6.86%
Promoter shares pledged
0%

Source: finedge · as of 2026-03-31

Similar companies

Source: quantro_company_profiles · as of 2026-10-23

Recent exchange filings

Source: nse · as of 2026-10-05

Frequently asked questions

What does Zydus Lifesciences Ltd do?
Zydus Lifesciences Ltd. engages in the discovery, development, and manufacture of pharmaceutical products under Zydus brand. The company is headquartered in Ahmedabad, Gujarat and currently employs 23,026 full-time employees. The firm is engaged in the research and development, manufacturing, marketing and selling of finished dosage human formulations, such as generics and specialty formulations, including biosimilars and vaccines; active pharmaceutical ingredients (APIs); animal healthcare products, and consumer wellness products. Its products include Bilypsa (saroglitizar), Oxemia (desidustat), Ujvira (biosimilar Kadcyla), and Exemptia. The company offers Bilypsa drug for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Desidustat is an oral, small molecule hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitor, which is used for the treatment of anemia in chronic kidney disease (CKD) patients. The company is also developing an oral small molecule ZYIL1, targeted at selectively suppressing inflammation caused by the NLRP3 inflammasome. Its ZyCoV-D is a plasmid deoxyribonucleic acid (DNA) vaccine for COVID-19.
Which sector is Zydus Lifesciences Ltd in?
Zydus Lifesciences Ltd is in the Pharmaceuticals sector, Pharmaceuticals & Biotechnology industry.
What are Zydus Lifesciences Ltd's latest annual revenue and profit?
For the year ended Mar 2026: revenue 27148.40 Cr, profit after tax 5040.00 Cr.
What is the promoter holding and pledge in Zydus Lifesciences Ltd?
Promoter holding is 75.00%; pledged shares are 0.00% of the promoter holding.
Which companies are similar to Zydus Lifesciences Ltd?
Companies in the same sector of similar size: Cipla Ltd, Lupin Ltd, Mankind Pharma Ltd, Dr Reddy's Laboratories Ltd, Aurobindo Pharma Ltd, Laurus Labs Ltd.
Want more history and detail? Create a free account for the full price history, quarterly statements, balance sheet and cash flow.

Figures computed 2026-10-23.